Screener
R&D at other companies
Other financials
Where this comes from
Reported directly by Nektar Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.
The source filing: Nektar Therapeutics’s 10-Q, filed May 8, 2026.
- Filed
- May 7, 2026, 8:00 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-212596
| Line item | Three Months Ended March 31, | Three Months Ended March 31, | Three Months Ended March 31, |
|---|---|---|---|
| Non-cash royalty revenue related to the sales of future royalties | $ | $$10,861 | 10,460 |
| Total revenue | 10,861 | 10,460 | |
| Operating costs and expenses: | |||
| Research and development (including $1,708 and $208 for the three months ended March 31, 2026 and 2025, respectively, from a related party) | 35,680 | 30,480 | |
| General and administrative | 13,439 | 24,346 | |
| Restructuring and impairment | 796 | 169 | |
| Total operating costs and expenses | 49,915 | 54,995 | |
| Loss from operations | (39,054) | (44,535) |
Item 1. Condensed Consolidated Financial Statements—Unaudited:
FAQ
- What is Nektar Therapeutics's R&D?
- Nektar Therapeutics (NKTR) reported R&D of $35.68M in Q1 2026.
- How has Nektar Therapeutics's R&D changed year-over-year?
- Nektar Therapeutics's R&D increased by 17.1% year-over-year, from $30.48M to $35.68M.
- What is the long-term trend for Nektar Therapeutics's R&D?
- Over 4 years (2021 to 2025), Nektar Therapeutics's R&D has grown at a -26.4% compound annual growth rate (CAGR), from $400.27M to $117.33M.
- What does R&D mean?
- Costs of research activities to discover new knowledge and development activities to translate research into new or improved products, services, processes, or technologies.
Ask your AI about Nektar Therapeutics's r&d.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude